查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1971888

CRISPR技術市場分析及預測（至2035年）：按類型、產品類型、服務、技術、應用、最終用戶、組件、部署類型、解決方案和發展階段分類

CRISPR Technology Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Application, End User, Component, Deployment, Solutions, Stage
出版日期: | 出版商: Global Insight Services | 英文 343 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

預計CRISPR技術市場規模將從2024年的36.254億美元成長到2034年的86.523億美元，複合年成長率約為15.8%。 CRISPR技術市場涵蓋基因編輯工具和解決方案，利用CRISPR-Cas9系統精確修改DNA。該市場橫跨生物技術、農業和製藥等領域，推動基因研究、作物改良和治療方法開發的發展。對個人化醫療和農業永續性發展日益成長的需求正在推動市場成長，並促進以遞送方式、脫靶效應和監管合規性為重點的創新。

受基因工程進步和研究應用拓展的推動，CRISPR技術市場正經歷強勁成長。其中，治療領域成長最為顯著，這主要得益於基因編輯療法在治療遺傳疾病的潛力。腫瘤學應用前景特別廣闊，可望為多種癌症提供新的治療方法。農業領域也緊隨其後，這主要受改良作物性狀和增強抗蟲害能力的需求所驅動。為了滿足永續農業實踐的需求，植物性因組編輯技術正受到廣泛關注。診斷領域也正在崛起，成為另一個高成長領域，基於CRISPR的診斷工具能夠快速、精準地檢測疾病。這一成長主要由感染疾病日益普遍以及對快速診斷解決方案的需求所驅動。對CRISPR技術的投資也不斷增加，製藥和生物技術公司處於行業前沿，推動創新和市場發展。

市場區隔
類型 基因組編輯、基因工程、基於CRISPR的治療方法、基於CRISPR的診斷
產品 CRISPR試劑盒、CRISPR文庫、CRISPR試劑、CRISPR質體、CRISPR酶
服務 基因編輯服務、細胞株設計、CRISPR篩檢服務、諮詢服務
科技 CRISPR/Cas9、CRISPR/Cas12a、CRISPR/Cas13、基礎編輯、主編輯
應用領域 生物醫學研究、農業研究、藥物研發、臨床應用、診斷
最終用戶 生技公司、製藥公司、學術和研究機構、受託研究機構
成分 引導RNA，供體DNA模板
部署 體內、體外、試管內
解決方案 客製化 CRISPR 解決方案，即用型解決方案
步 藥物發現研究階段、臨床前階段、臨床階段、商業化階段

市場概況：

隨著主要企業透過策略性產品推出不斷拓展產品組合，CRISPR技術市場正經歷市場佔有率的動態變化。各公司正在調整定價策略，以平衡產品的可及性和創新性。市場的一個顯著特徵是新參與企業數量的快速成長，每個新進業者都試圖利用CRISPR的變革潛力。現有企業則專注於提升產品的精準度和效率，以在競爭中脫穎而出。基因編輯技術在農業、醫療保健和生物技術等各個領域的應用進展，推動了這個蓬勃發展的市場的形成。 CRISPR技術市場的競爭異常激烈，主要企業競相爭取技術優勢。基準分析表明，那些在研發方面投入巨資的公司正在製定行業標準。監管的影響在北美和歐洲等地區尤其顯著，這些地區嚴格的指導方針塑造著市場動態。這些法規旨在確保倫理考量，並影響產品開發週期。此外，學術機構和商業組織之間的合作也對市場產生影響，並促進創新。這些夥伴關係對於克服監管挑戰和加速市場准入至關重要，使 CRISPR 技術市場成為科學和商業性活動的中心。

主要趨勢和促進因素：

受基因編輯技術在各領域應用進展的推動，CRISPR技術市場正經歷強勁成長。一個關鍵趨勢是CRISPR技術在農業領域的應用日益廣泛，透過提高作物產量和增強抗蟲害能力，有助於應對糧食安全挑戰。在醫療保健領域，CRISPR正在革新個人化醫療，為遺傳性疾病和罕見疾病提供潛在治療方法。藥廠正在利用CRISPR技術進行藥物發現與開發，加速創新治療方法的研發進程。基於CRISPR的診斷工具的興起是另一個新興趨勢，能夠快速且準確地檢測感染疾病。政府和私部門的監管支持和資金投入是研發活動的關鍵驅動力。倫理考量和社會接受度正在塑造市場動態，並影響法規結構和投資決策。隨著CRISPR技術的不斷發展，投資研發和拓展其應用的公司將迎來盈利的機會。

限制與挑戰：

CRISPR技術市場面臨許多重大限制與挑戰。其中一項主要挑戰是圍繞基因編輯的倫理問題，這引發了公眾的焦慮和監管機構的審查。這場道德辯論可能會延緩核准流程，並限制市場擴張。此外，CRISPR技術潛在的脫靶效應也帶來了科學難題。這些非預期的基因修飾可能產生不可預測的後果，因此需要進一步的研究和開發來提高其準確性和安全性。 CRISPR技術的高成本也是一大障礙，使其主要面向資金雄厚的機構和公司。這一經濟門檻限制了其在各領域的廣泛應用。知識產權糾紛也是一項重大挑戰。複雜的專利情況可能導致法律糾紛，並阻礙產業內的創新與合作。最後，精通CRISPR技術的專業人員短缺。這種技能缺口阻礙了CRISPR解決方案在各個領域的有效應用和發展。

目錄

第1章執行摘要

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機遇
  • 市場限制
  • 複合年均成長率：成長分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章 細分市場分析

  • 市場規模及預測：依類型
    • 基因組編輯
    • 基因工程
    • 基於CRISPR的療法
    • 基於CRISPR的診斷
  • 市場規模及預測：依產品分類
    • CRISPR試劑盒
    • CRISPR文庫
    • CRISPR試劑
    • CRISPR質體
    • CRISPR酶
  • 市場規模及預測：依服務分類
    • 基因編輯服務
    • 細胞株工程
    • CRISPR篩檢服務
    • 諮詢服務
  • 市場規模及預測：依技術分類
    • CRISPR/Cas9
    • CRISPR/Cas12a
    • CRISPR/Cas13
    • 基礎編輯
    • Prime Edit
  • 市場規模及預測：依應用領域分類
    • 生物醫學研究
    • 農業調查
    • 藥物研發
    • 臨床應用
    • 診斷
  • 市場規模及預測：依最終用戶分類
    • 生技公司
    • 製藥公司
    • 學術和研究機構
    • 合約研究機構
  • 市場規模及預測：依組件分類
    • 引導RNA
    • 供體DNA模板
  • 市場規模及預測：依發展狀況
    • In vivo
    • Ex Vivo
    • 體外
  • 市場規模及預測：按解決方案分類
    • 客製化 CRISPR 解決方案
    • 即用型解決方案
  • 市場規模及預測：依發展階段分類
    • 發現
    • 臨床前階段
    • 臨床
    • 商業的

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地區
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲地區

第6章 市場策略

  • 需求與供給差距分析
  • 貿易和物流限制
  • 價格、成本和利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 法規概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 主要企業的策略

第8章：公司簡介

  • CRISPR Therapeutics
  • Editas Medicine
  • Intellia Therapeutics
  • Caribou Biosciences
  • Beam Therapeutics
  • Mammoth Biosciences
  • Synthego
  • Cellectis
  • Precision Biosciences
  • eGenesis
  • Ergomed
  • Locus Biosciences
  • Inscripta
  • Metagenomi
  • Pairwise

第9章：關於我們

簡介目錄
Product Code: GIS33752

CRISPR Technology Market is anticipated to expand from $3,625.4 million in 2024 to $8,652.3 million by 2034, growing at a CAGR of approximately 15.8%. The CRISPR Technology Market encompasses tools and solutions for gene editing, utilizing CRISPR-Cas9 systems to modify DNA with precision. This market spans sectors such as biotechnology, agriculture, and pharmaceuticals, driving advancements in genetic research, crop enhancement, and therapeutic development. The increasing demand for personalized medicine and agricultural sustainability fuels growth, with innovations focusing on delivery methods, off-target effects, and regulatory compliance.

The CRISPR Technology Market is experiencing robust growth, driven by advancements in genetic engineering and increasing research applications. The therapeutics segment is the top-performing area, with gene editing therapies leading the charge due to their potential to treat genetic disorders. Within this segment, oncology applications are particularly promising, offering novel treatment avenues for various cancers. The agriculture segment follows closely, driven by the need for improved crop traits and pest resistance. Plant genome editing is gaining significant traction, reflecting the demand for sustainable agricultural practices. Diagnostics is emerging as a secondary high-performing segment, with CRISPR-based diagnostic tools offering rapid and precise disease detection capabilities. This growth is fueled by the rising prevalence of infectious diseases and the need for quick diagnostic solutions. Investment in CRISPR technology is also expanding, with pharmaceutical and biotech companies at the forefront, fostering innovation and driving market evolution.

Market Segmentation
TypeGenome Editing, Genetic Engineering, CRISPR-based Therapeutics, CRISPR-based Diagnostics
ProductCRISPR Kits, CRISPR Libraries, CRISPR Reagents, CRISPR Plasmids, CRISPR Enzymes
ServicesGene Editing Services, Cell Line Engineering, CRISPR Screening Services, Consulting Services
TechnologyCRISPR/Cas9, CRISPR/Cas12a, CRISPR/Cas13, Base Editing, Prime Editing
ApplicationBiomedical Research, Agricultural Research, Drug Development, Clinical Applications, Diagnostics
End UserBiotechnology Companies, Pharmaceutical Companies, Academic & Research Institutes, Contract Research Organizations
ComponentGuide RNA, Donor DNA Templates
DeploymentIn Vivo, Ex Vivo, In Vitro
SolutionsCustom CRISPR Solutions, Ready-to-use Solutions
StageDiscovery, Preclinical, Clinical, Commercial

Market Snapshot:

The CRISPR Technology Market is witnessing a dynamic shift in market share, with key players expanding their portfolios through strategic product launches. Pricing strategies are evolving as companies seek to balance accessibility with innovation. The landscape is characterized by a surge in new entrants, each aiming to capitalize on the transformative potential of CRISPR. Established firms are focusing on enhancing the precision and efficiency of their offerings, driving competitive differentiation. This vibrant market is fueled by advancements in gene editing applications across various sectors, including agriculture, healthcare, and biotechnology. Competition in the CRISPR Technology Market is intense, with leading companies vying for technological supremacy. Benchmarking reveals that firms investing heavily in R&D are setting industry standards. Regulatory influences are significant, particularly in regions like North America and Europe, where stringent guidelines shape market dynamics. These regulations ensure ethical considerations are met, impacting product development timelines. The market is further influenced by collaborations between academic institutions and commercial entities, fostering innovation. Such partnerships are pivotal in overcoming regulatory challenges and accelerating market entry, making the CRISPR Technology Market a hub of scientific and commercial activity.

Geographical Overview:

The CRISPR technology market is experiencing robust growth across various regions, each showcasing unique potential. North America remains at the forefront, driven by substantial investments in biotechnology and a strong focus on genetic research. The presence of leading biotech firms and research institutions further accelerates market development. Europe is not far behind, with significant government support and funding initiatives fostering innovation in gene editing. The region's regulatory landscape, which emphasizes ethical considerations, also contributes to a balanced growth environment. In the Asia Pacific, the market is rapidly expanding, underpinned by increasing research activities and collaborations between academic and commercial entities. Countries like China and Japan are emerging as key players due to their strong focus on technological advancement. Latin America and the Middle East & Africa are witnessing nascent growth stages, with rising awareness and investments in genetic research. These regions are recognizing CRISPR's potential to address healthcare challenges and drive scientific progress.

Key Trends and Drivers:

The CRISPR Technology Market is experiencing robust growth, driven by advancements in gene-editing applications across various sectors. A key trend is the increasing utilization of CRISPR in agriculture, where it enhances crop yield and resistance to pests, thereby addressing food security challenges. In the healthcare sector, CRISPR is revolutionizing personalized medicine, offering potential cures for genetic disorders and rare diseases. Pharmaceutical companies are leveraging CRISPR for drug discovery and development, accelerating the pace of creating innovative treatments. The rise of CRISPR-based diagnostic tools is another trend, providing rapid and accurate detection of infectious diseases. Regulatory support and funding from governments and private sectors are significant drivers, facilitating research and development activities. Ethical considerations and public acceptance are shaping market dynamics, influencing regulatory frameworks and investment decisions. As CRISPR technology continues to evolve, it presents lucrative opportunities for companies investing in research and expanding their application portfolios.

Restraints and Challenges:

The CRISPR Technology Market faces several significant restraints and challenges. One primary challenge is the ethical concerns surrounding gene editing, which raise public apprehension and regulatory scrutiny. This moral debate can slow down the approval process and limit market expansion. Additionally, the potential off-target effects of CRISPR technology pose a scientific challenge. These unintended genetic modifications can lead to unpredictable outcomes, necessitating further research and development to enhance precision and safety. The high cost of CRISPR technology is another barrier, restricting access primarily to well-funded institutions and companies. This financial hurdle limits widespread adoption and application in diverse fields. Intellectual property disputes also present a significant challenge. Complicated patent landscapes can lead to legal battles, stifling innovation and collaboration within the industry. Lastly, there is a lack of skilled professionals proficient in CRISPR technology. This skills gap hampers the efficient implementation and advancement of CRISPR-based solutions across various sectors.

Key Players:

CRISPR Therapeutics, Editas Medicine, Intellia Therapeutics, Caribou Biosciences, Beam Therapeutics, Mammoth Biosciences, Synthego, Cellectis, Precision Biosciences, eGenesis, Ergomed, Locus Biosciences, Inscripta, Metagenomi, Pairwise

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Application
  • 2.6 Key Market Highlights by End User
  • 2.7 Key Market Highlights by Component
  • 2.8 Key Market Highlights by Deployment
  • 2.9 Key Market Highlights by Solutions
  • 2.10 Key Market Highlights by Stage

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Genome Editing
    • 4.1.2 Genetic Engineering
    • 4.1.3 CRISPR-based Therapeutics
    • 4.1.4 CRISPR-based Diagnostics
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 CRISPR Kits
    • 4.2.2 CRISPR Libraries
    • 4.2.3 CRISPR Reagents
    • 4.2.4 CRISPR Plasmids
    • 4.2.5 CRISPR Enzymes
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Gene Editing Services
    • 4.3.2 Cell Line Engineering
    • 4.3.3 CRISPR Screening Services
    • 4.3.4 Consulting Services
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 CRISPR/Cas9
    • 4.4.2 CRISPR/Cas12a
    • 4.4.3 CRISPR/Cas13
    • 4.4.4 Base Editing
    • 4.4.5 Prime Editing
  • 4.5 Market Size & Forecast by Application (2020-2035)
    • 4.5.1 Biomedical Research
    • 4.5.2 Agricultural Research
    • 4.5.3 Drug Development
    • 4.5.4 Clinical Applications
    • 4.5.5 Diagnostics
  • 4.6 Market Size & Forecast by End User (2020-2035)
    • 4.6.1 Biotechnology Companies
    • 4.6.2 Pharmaceutical Companies
    • 4.6.3 Academic & Research Institutes
    • 4.6.4 Contract Research Organizations
  • 4.7 Market Size & Forecast by Component (2020-2035)
    • 4.7.1 Guide RNA
    • 4.7.2 Donor DNA Templates
  • 4.8 Market Size & Forecast by Deployment (2020-2035)
    • 4.8.1 In Vivo
    • 4.8.2 Ex Vivo
    • 4.8.3 In Vitro
  • 4.9 Market Size & Forecast by Solutions (2020-2035)
    • 4.9.1 Custom CRISPR Solutions
    • 4.9.2 Ready-to-use Solutions
  • 4.10 Market Size & Forecast by Stage (2020-2035)
    • 4.10.1 Discovery
    • 4.10.2 Preclinical
    • 4.10.3 Clinical
    • 4.10.4 Commercial

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Application
      • 5.2.1.6 End User
      • 5.2.1.7 Component
      • 5.2.1.8 Deployment
      • 5.2.1.9 Solutions
      • 5.2.1.10 Stage
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Application
      • 5.2.2.6 End User
      • 5.2.2.7 Component
      • 5.2.2.8 Deployment
      • 5.2.2.9 Solutions
      • 5.2.2.10 Stage
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Application
      • 5.2.3.6 End User
      • 5.2.3.7 Component
      • 5.2.3.8 Deployment
      • 5.2.3.9 Solutions
      • 5.2.3.10 Stage
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Application
      • 5.3.1.6 End User
      • 5.3.1.7 Component
      • 5.3.1.8 Deployment
      • 5.3.1.9 Solutions
      • 5.3.1.10 Stage
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Application
      • 5.3.2.6 End User
      • 5.3.2.7 Component
      • 5.3.2.8 Deployment
      • 5.3.2.9 Solutions
      • 5.3.2.10 Stage
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Application
      • 5.3.3.6 End User
      • 5.3.3.7 Component
      • 5.3.3.8 Deployment
      • 5.3.3.9 Solutions
      • 5.3.3.10 Stage
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Application
      • 5.4.1.6 End User
      • 5.4.1.7 Component
      • 5.4.1.8 Deployment
      • 5.4.1.9 Solutions
      • 5.4.1.10 Stage
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Application
      • 5.4.2.6 End User
      • 5.4.2.7 Component
      • 5.4.2.8 Deployment
      • 5.4.2.9 Solutions
      • 5.4.2.10 Stage
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Application
      • 5.4.3.6 End User
      • 5.4.3.7 Component
      • 5.4.3.8 Deployment
      • 5.4.3.9 Solutions
      • 5.4.3.10 Stage
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Application
      • 5.4.4.6 End User
      • 5.4.4.7 Component
      • 5.4.4.8 Deployment
      • 5.4.4.9 Solutions
      • 5.4.4.10 Stage
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Application
      • 5.4.5.6 End User
      • 5.4.5.7 Component
      • 5.4.5.8 Deployment
      • 5.4.5.9 Solutions
      • 5.4.5.10 Stage
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Application
      • 5.4.6.6 End User
      • 5.4.6.7 Component
      • 5.4.6.8 Deployment
      • 5.4.6.9 Solutions
      • 5.4.6.10 Stage
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Application
      • 5.4.7.6 End User
      • 5.4.7.7 Component
      • 5.4.7.8 Deployment
      • 5.4.7.9 Solutions
      • 5.4.7.10 Stage
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Application
      • 5.5.1.6 End User
      • 5.5.1.7 Component
      • 5.5.1.8 Deployment
      • 5.5.1.9 Solutions
      • 5.5.1.10 Stage
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Application
      • 5.5.2.6 End User
      • 5.5.2.7 Component
      • 5.5.2.8 Deployment
      • 5.5.2.9 Solutions
      • 5.5.2.10 Stage
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Application
      • 5.5.3.6 End User
      • 5.5.3.7 Component
      • 5.5.3.8 Deployment
      • 5.5.3.9 Solutions
      • 5.5.3.10 Stage
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Application
      • 5.5.4.6 End User
      • 5.5.4.7 Component
      • 5.5.4.8 Deployment
      • 5.5.4.9 Solutions
      • 5.5.4.10 Stage
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Application
      • 5.5.5.6 End User
      • 5.5.5.7 Component
      • 5.5.5.8 Deployment
      • 5.5.5.9 Solutions
      • 5.5.5.10 Stage
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Application
      • 5.5.6.6 End User
      • 5.5.6.7 Component
      • 5.5.6.8 Deployment
      • 5.5.6.9 Solutions
      • 5.5.6.10 Stage
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Application
      • 5.6.1.6 End User
      • 5.6.1.7 Component
      • 5.6.1.8 Deployment
      • 5.6.1.9 Solutions
      • 5.6.1.10 Stage
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Application
      • 5.6.2.6 End User
      • 5.6.2.7 Component
      • 5.6.2.8 Deployment
      • 5.6.2.9 Solutions
      • 5.6.2.10 Stage
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Application
      • 5.6.3.6 End User
      • 5.6.3.7 Component
      • 5.6.3.8 Deployment
      • 5.6.3.9 Solutions
      • 5.6.3.10 Stage
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Application
      • 5.6.4.6 End User
      • 5.6.4.7 Component
      • 5.6.4.8 Deployment
      • 5.6.4.9 Solutions
      • 5.6.4.10 Stage
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Application
      • 5.6.5.6 End User
      • 5.6.5.7 Component
      • 5.6.5.8 Deployment
      • 5.6.5.9 Solutions
      • 5.6.5.10 Stage

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 CRISPR Therapeutics
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Editas Medicine
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Intellia Therapeutics
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Caribou Biosciences
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Beam Therapeutics
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Mammoth Biosciences
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Synthego
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Cellectis
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Precision Biosciences
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 eGenesis
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Ergomed
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Locus Biosciences
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Inscripta
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Metagenomi
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Pairwise
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us